mRNA-LNP Vaccines

Lipid nanoparticles (LNPs) are typically composed of ionizable cationic lipids (ICLs), helper lipids, cholesterol, and polyethylene glycol (PEG) lipids. LNPs have become prominent non-viral carriers for mRNA delivery in clinical applications. By encapsulating mRNA within a lipid core, LNPs protect it from degradation, enhance cellular uptake, and promote cytoplasmic release upon entry into target cells.

mRNA–LNP therapy is characterized by precise targeting, high delivery efficiency, and favorable safety, make it a promising therapeutic approach for various diseases.

• China’s Only Breakthrough Patent for Core Bottleneck Technology
• Breaks International Patent Monopoly | Universal LNP Formulation | Global Commercial Layout
• Patents Granted in USA, Russia, Japan, Australia, South Korea, New Zealand